Opioid

Key Trigger Of Opioid Withdrawal Symptoms Found

Researchers have discovered an important chemical in the brain's neuronal machinery that triggers some of the withdrawal symptoms of opioid drugs like morphine and heroin. They believe that drugs to inhibit the chemical--called a transporter--could relieve some of the early physical symptoms of withdrawal, such as teeth-chattering, uncontrolled shaking, and jumpiness. Such drugs could bec...

Opioid at Biology Products

Rabbit Anti-mu Opioid Receptor splice variant Antibody, Unconjugated from ABR-Affinity BioReagents

Description:mu Opioid Receptor splice variant -20 C, Avoid Freeze/Thaw Cycles...
Company:ABR-Affinity BioReagents

Anti-Opioid Receptor, mu, phospho (Ser375) Antibody, Unconjugated from Cell Signaling Technology

Description:Phospho-mu-Opioid Receptor (Ser375) Antibody...
Company:Cell Signaling Technology

Opioid at Biology Technology

No data found

Search Opioid biology technology at Google

Search Opioid biology technology at Yahoo

Search Opioid biology technology at Msn

Opioid at Medicine News

Back pain treated with Opioids

Researchers at the University of Dallas have observed that Opioid analgesics should be considered before opting for surgery in severe chronic back pain. The opioid analgesics, such as morphine, fentanyl and oxycodone,// are strong pain-relievers most often used to relieve cancer pain. But a review of the evidence suggests they may also have a role in relieving chronic back pain. Docto...

Ambiguous Efficacy Of Opioid Drugs In Chronic Inflammatory Joint Pain Relief

Endomorphins are highly powerful a tool for pain management, just as morphine, a problematic narcotic derived from the opium poppy. It has previously been found that endomorphins are able to sidestep concerns// of side effects by virtue of their hard-wired relationship to the body's own pain control receptors. Such receptors, known as u-opioids, appear to be highly sensitized to endomorphins, sel...

Opioids And Abnormal Pain Perception

A growing number of animal and human studies show that under certain circumstances, opioids can elicit unexpected changes in pain sensitivity, resulting in hyperalgesia (abnormally intense pain in response to painful// stimulation) and allodynia (abnormally intense pain in response to non-painful stimulation). Interestingly, previous studies have found evidence for hyperalgesi...

Sudden Opioid Withdrawal Results in ‘Broken Heart Syndrome

Two new studies published in the Mayo Clinic Proceedings revealed a link existing between sudden opioid withdrawal and cocaine use with the onset of cardiac syndromes.// ‘Broken Heart Syndrome’, which was characterized by chest pain, shortness of breath mimics heart attack. The findings shed light on ‘broken heart syndrome,’ a still somewhat uncommon disorder first described i...

Overdose of Opioid Painkillers Can Kill Pain and The Patient

The most common drugs responsible for deaths due to overdose happens to be opioid painkillers which are procured illegally without a prescription//, say researchers. According to the researchers, powerful opioid drugs like oxycodone or fentanyl are now being frequently prescribed by Doctors, with a motive to realizing better results in chronic pain management. Not surprising that, t...

More>>

Opioid at Medicine Products

No data found

Search Opioid medicine products at Google

Search Opioid medicine products at Yahoo

Search Opioid medicine products at Msn

Opioid at Medicine Technology

Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness

TARRYTOWN, N.Y. & MADISON, N.J.--(BUSINESS WIRE)--Jun 28, 2007- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX) and WyethPharmaceuticals, a division of Wyeth (NYSE: WYE), today announcedpositive results from a three-month open-label extension study ofsubcutaneous methylnaltrexone for the treatment of opioid-inducedconstipation (OIC) in patients with advanced illness. The resultsare sched...

Expert Opinion Highlights Avigen's AV411 as Potential New Therapeutic for Neuropathic Pain and Opioid Withdrawal

Focus On AV411's Unique Mechanism of Action and Broad Potential forthe Treatment of Neurological Conditions ALAMEDA, Calif., June 26, 2007 (PRIME NEWSWIRE) -- Avigen, Inc.(Nasdaq:AVGN), a biopharmaceutical company innovating therapeuticsfor the treatment of neurological conditions, announced today thatExpert Opinion on Investigational Drugs has published an articlefeaturing...

Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments

Addiction can lead to hospitalization and drug withdrawal CHICAGO, May 15, 2007 /PRNewswire/ -- A new survey of hundredsof migraine patients and physicians commissioned by the NationalHeadache Foundation and conducted by Harris Interactive shows that20 percent of migraine patients are currently taking potentiallyaddictive medications that contain barbiturates or opioids and havenot been a...

Alpharma Presents Positive Pharmacokinetic Study Results of Its Investigational Abuse-Deterrent, Extended-Release Opioid

BRIDGEWATER, N.J., May 03, 2007 /PRNewswire-FirstCall/ --Alpharma Inc. , a leading global specialty pharmaceutical companythrough its Pharmaceuticals Division, this week presented positiveresults of a pharmacokinetic study of its investigationalabuse-deterrent, extended-release opioid at the 26th annualscientific meeting of the American Pain Society in Washington, D.C.The data demonstrat...